1-3 of 3
Ruth LaPushin
Close
Sort by
Journal Articles

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

Clinical Trials & Observations
Mariela Sivina, Elena Hartmann, Thomas J. Kipps, Laura Rassenti, Diana Krupnik, Susan Lerner, Ruth LaPushin, Lianchun Xiao, Xuelin Huang, Lillian Werner, Donna Neuberg, Hagop Kantarjian, Susan O'Brien, William G. Wierda, Michael J. Keating, Andreas Rosenwald, Jan A. Burger
Journal: Blood
Blood (2011) 117 (5): 1662–1669.
https://doi.org/10.1182/blood-2010-09-307249
Published: 2011
Includes: Supplemental data
Journal Articles

HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance

Nina Shah, MD, William Decker, Ruth Lapushin, Dongxia Xing, Simon Robinson, PhD, Hong Yang, PHD, Simrit Parmar, M.D., Shawndeep Tung, MD, Susan O'Brien, Marcelo Fernandez-Vina, Elizabeth J. Shpall, William G. Wierda, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1370.
https://doi.org/10.1182/blood.V116.21.1370.1370
Published: 2010
Journal Articles

CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment.

Mariela Sivina, Elena Hartmann, MD, Diana Krupnik, Ruth LaPushin, Michael Keating, MD, Thomas J. Kipps, MD, PhD, Andreas Rosenwald, William G Wierda, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 358.
https://doi.org/10.1182/blood.V114.22.358.358
Published: 2009